Our in vivo mouse model findings (Figure 3), coupled with these clinical observations, suggest that loss of RBM10 can limit the initial response to EGFR-targeted therapy by suppressing tumor cell apoptosis, leading to worse clinical outcomes for patients with EGFR-mutant LA. This evidence concerns the gene EGFR and neoplasm.